1
|
Castro EM, Lotfipour S, Leslie FM. Nicotine on the developing brain. Pharmacol Res 2023; 190:106716. [PMID: 36868366 PMCID: PMC10392865 DOI: 10.1016/j.phrs.2023.106716] [Citation(s) in RCA: 9] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/15/2022] [Revised: 02/23/2023] [Accepted: 02/28/2023] [Indexed: 03/05/2023]
Abstract
Developmental periods such as gestation and adolescence have enhanced plasticity leaving the brain vulnerable to harmful effects from nicotine use. Proper brain maturation and circuit organization is critical for normal physiological and behavioral outcomes. Although cigarette smoking has declined in popularity, noncombustible nicotine products are readily used. The misperceived safety of these alternatives lead to widespread use among vulnerable populations such as pregnant women and adolescents. Nicotine exposure during these sensitive developmental windows is detrimental to cardiorespiratory function, learning and memory, executive function, and reward related circuitry. In this review, we will discuss clinical and preclinical evidence of the adverse alterations in the brain and behavior following nicotine exposure. Time-dependent nicotine-induced changes in reward related brain regions and drug reward behaviors will be discussed and highlight unique sensitivities within a developmental period. We will also review long lasting effects of developmental exposure persisting into adulthood, along with permanent epigenetic changes in the genome which can be passed to future generations. Taken together, it is critical to evaluate the consequences of nicotine exposure during these vulnerable developmental windows due to its direct impact on cognition, potential trajectories for other substance use, and implicated mechanisms for the neurobiology of substance use disorders.
Collapse
Affiliation(s)
- Emily M Castro
- Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, University of California, Irvine, Irvine, CA, USA
| | - Shahrdad Lotfipour
- Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, University of California, Irvine, Irvine, CA, USA; Department of Emergency Medicine, School of Medicine, University of California, Irvine, Irvine, CA, USA; Department of Pathology and Laboratory Medicine, School of Medicine, University of California, Irvine, Irvine, CA, USA
| | - Frances M Leslie
- Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, University of California, Irvine, Irvine, CA, USA.
| |
Collapse
|
2
|
Hossain MK, Davidson M, Kypreos E, Feehan J, Muir JA, Nurgali K, Apostolopoulos V. Immunotherapies for the Treatment of Drug Addiction. Vaccines (Basel) 2022; 10:vaccines10111778. [PMID: 36366287 PMCID: PMC9697687 DOI: 10.3390/vaccines10111778] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/01/2022] [Revised: 10/10/2022] [Accepted: 10/12/2022] [Indexed: 11/05/2022] Open
Abstract
Substance use disorders (SUD) are a serious public health concern globally. Existing treatment platforms suffer from a lack of effectiveness. The development of immunotherapies against these substances of abuse for both prophylactic and therapeutic use has gained tremendous importance as an alternative and/or supplementary to existing therapies. Significant development has been made in this area over the last few decades. Herein, we highlight the vaccine and other biologics development strategies, preclinical, clinical updates along with challenges and future directions. Articles were searched in PubMed, ClinicalTrial.gov, and google electronic databases relevant to development, preclinical, clinical trials of nicotine, cocaine, methamphetamine, and opioid vaccines. Various new emerging vaccine development strategies for SUD were also identified through this search and discussed. A good number of vaccine candidates demonstrated promising results in preclinical and clinical phases and support the concept of developing a vaccine for SUD. However, there have been no ultimate success as yet, and there remain some challenges with a massive push to take more candidates to clinical trials for further evaluation to break the bottleneck.
Collapse
Affiliation(s)
- Md Kamal Hossain
- Institute for Health and Sport, Victoria University, Melbourne, VIC 3030, Australia
| | - Majid Davidson
- Institute for Health and Sport, Victoria University, Melbourne, VIC 3030, Australia
| | - Erica Kypreos
- College of Health and Biomedicine, Victoria University, Melbourne, VIC 3021, Australia
| | - Jack Feehan
- Institute for Health and Sport, Victoria University, Melbourne, VIC 3030, Australia
- Regenerative Medicine and Stem Cells Program, Australian Institute of Musculoskeletal Science (AIMSS), Melbourne, VIC 3021, Australia
| | - Joshua Alexander Muir
- College of Health and Biomedicine, Victoria University, Melbourne, VIC 3021, Australia
| | - Kulmira Nurgali
- Institute for Health and Sport, Victoria University, Melbourne, VIC 3030, Australia
- Department of Medicine Western Health, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Melbourne, VIC 3021, Australia
- Immunology Program, Australian Institute of Musculoskeletal Science (AIMSS), Melbourne, VIC 3021, Australia
| | - Vasso Apostolopoulos
- Institute for Health and Sport, Victoria University, Melbourne, VIC 3030, Australia
- Regenerative Medicine and Stem Cells Program, Australian Institute of Musculoskeletal Science (AIMSS), Melbourne, VIC 3021, Australia
- Correspondence:
| |
Collapse
|
3
|
Sand KMK, Gruber MM, Sandlie I, Mathiesen L, Andersen JT, Wadsack C. Contribution of the ex vivo placental perfusion model in understanding transplacental immunoglobulin G transfer. Placenta 2022; 127:77-87. [PMID: 35981406 DOI: 10.1016/j.placenta.2022.07.019] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/07/2022] [Revised: 07/07/2022] [Accepted: 07/28/2022] [Indexed: 11/24/2022]
Abstract
INTRODUCTION The acquisition of humoral immunity in utero is essential for the fetus. The crucial protein, which is responsible for this part of immunity, is immunoglobulin-G (IgG). Immune functions of IgGs are mediated via the interaction of the crystallizable fragment (Fc) region of IgG with specific Fc γ receptors (FcγRs). However, an atypical FcγR, the neonatal Fc receptor (FcRn), is a key regulator of IgG transfer across the human placenta. During the last four decades ex vivo placental perfusion studies have contributed significantly to the study of mechanisms of IgG transfer across the multicellular placental barrier. METHOD A PubMed search was conducted by using specific keywords: placenta, perfusion and IgG to review manuscripts using human placental perfusion to study the transplacental transfer of IgG. Relevant studies found in reference lists of these manuscripts were also added to the review, and references were included that supported or gave nuance to the discussion of the mechanisms of IgG kinetics in the placenta. RESULTS AND DISCUSSION We found twenty publications on the study of transplacental transfer of IgG using human ex vivo placental perfusion, by research groups with partly different settings. This review summarizes knowledge about placental IgG transfer, with a strong focus on the contributions from ex vivo placental perfusion studies.
Collapse
Affiliation(s)
- Kine Marita Knudsen Sand
- Department of Biosciences, University of Oslo, 0371, Oslo, Norway; Department of Immunology, Oslo University Hospital Rikshospitalet and University of Oslo, 0424, Oslo, Norway; Department of Pharmacology, Institute of Clinical Medicine, University of Oslo and Oslo University Hospital, 0424, Oslo, Norway
| | - Michael M Gruber
- Department of Obstetrics and Gynaecology, Medical University of Graz, 8036, Graz, Austria
| | - Inger Sandlie
- Department of Biosciences, University of Oslo, 0371, Oslo, Norway; Department of Immunology, Oslo University Hospital Rikshospitalet and University of Oslo, 0424, Oslo, Norway; Department of Pharmacology, Institute of Clinical Medicine, University of Oslo and Oslo University Hospital, 0424, Oslo, Norway
| | - Line Mathiesen
- Section of Environmental Health, Department of Public Health, University of Copenhagen, Copenhagen, Denmark.
| | - Jan Terje Andersen
- Department of Immunology, Oslo University Hospital Rikshospitalet and University of Oslo, 0424, Oslo, Norway; Department of Pharmacology, Institute of Clinical Medicine, University of Oslo and Oslo University Hospital, 0424, Oslo, Norway
| | - Christian Wadsack
- Department of Obstetrics and Gynaecology, Medical University of Graz, 8036, Graz, Austria; BioTechMed-Graz, Austria
| |
Collapse
|
4
|
Ali S, Albekairi N, Wang XM, Patrikeeva S, Nanovskaya TN, Ahmed MS, Rytting E. Determination of the Transplacental Transfer of Paclitaxel and Antipyrine by High Performance Liquid Chromatography Coupled with Photodiode Array Detector. J LIQ CHROMATOGR R T 2018; 41:232-238. [PMID: 30774296 DOI: 10.1080/10826076.2018.1436068] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Abstract
Ex vivo placental perfusion experiments are important in understanding the quantity and mechanisms of xenobiotic transport to the fetus during pregnancy. Our study demonstrates that paclitaxel and antipyrine concentrations in placental perfusion medium containing physiological concentrations of human serum albumin during pregnancy (30 mg/mL) can be quantified by RP-HPLC and UV detection. A liquid-liquid extraction method was developed for the quantification of paclitaxel and celecoxib (internal standard) from perfusion medium. Antipyrine, which is a necessary marker in placental perfusions for determining the validity of experiments and calculating the clearance index of xenobiotics, was also analyzed by HPLC and UV detection. Antipyrine concentrations were determined by HPLC after precipitating the perfusion medium in acetonitrile and separating the precipitated proteins by centrifugation. Concentrations were fitted to linear regressions with R2 values approaching 1. Lower limits of detection for paclitaxel and antipyrine were 100 ng/mL and 200 ng/mL, respectively. Both methods demonstrated high intra-day and inter-day precision and trueness. Additionally, the use of these methods was demonstrated in a placental perfusion experiment using Taxol® (paclitaxel dissolved in Cremophor-EL). The fetal transfer rate of Taxol was 6.6% after 1 hour.
Collapse
Affiliation(s)
- Shariq Ali
- Department of Pharmacology and Toxicology, The University of Texas Medical Branch, 301 University Blvd. Galveston, TX
| | - Norah Albekairi
- College of Pharmacy, King Saud University, King Khalid Road, Riyadh, Saudi Arabia
| | - Xiao-Ming Wang
- Department of Obstetrics and Gynecology, The University of Texas Medical Branch, 301 University Blvd. Galveston, TX
| | - Svetlana Patrikeeva
- Department of Obstetrics and Gynecology, The University of Texas Medical Branch, 301 University Blvd. Galveston, TX
| | - Tatiana N Nanovskaya
- Department of Obstetrics and Gynecology, The University of Texas Medical Branch, 301 University Blvd. Galveston, TX
| | - Mahmoud S Ahmed
- Department of Pharmacology and Toxicology, The University of Texas Medical Branch, 301 University Blvd. Galveston, TX.,Department of Obstetrics and Gynecology, The University of Texas Medical Branch, 301 University Blvd. Galveston, TX
| | - Erik Rytting
- Department of Pharmacology and Toxicology, The University of Texas Medical Branch, 301 University Blvd. Galveston, TX.,Department of Obstetrics and Gynecology, The University of Texas Medical Branch, 301 University Blvd. Galveston, TX
| |
Collapse
|
5
|
Shah M, Bourner L, Ali S, Al-Enazy S, Youssef MM, Fisler M, Rytting E. HPLC Method Development for Quantification of Doxorubicin in Cell Culture and Placental Perfusion Media. SEPARATIONS 2018; 5. [PMID: 29984222 PMCID: PMC6035002 DOI: 10.3390/separations5010009] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open
Abstract
Assessment of drug transport across the placenta is important in understanding the effect of drugs on placental and fetal health. These phenomena can be studied in both in vitro cell lines and ex vivo placental perfusions. We have successfully developed a sensitive yet simple high performance liquid chromatography (HPLC) method coupled with fluorescence detection to determine the concentration of doxorubicin (DXR) in cell culture media for transport studies in human trophoblast cells (BeWo, b30 clone) and in fetal media for placental perfusion experiments. The method was developed based on a protein precipitation technique and was validated in both media types for linearity, intra-day, and inter-day precision and accuracy. The relationship of peak area to concentration was linear with R2 values of 0.99 or greater obtained over the concentration range of 1.5 to 15,000 ng/mL. Despite the high concentrations of albumin in fetal perfusion media (30 mg/mL), the lower limits of detection and quantification for DXR were found to be 1.5 and 5 ng/mL, respectively. This analytical method may be used to study the transport of DXR across BeWo cells and human placenta during placental perfusion studies.
Collapse
Affiliation(s)
- Mansi Shah
- Department of Obstetrics & Gynecology, University of Texas Medical Branch, 301 University Boulevard, Galveston, TX 77555-1062, USA
| | - Luke Bourner
- Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, TX 77555-1062, USA
| | - Shariq Ali
- Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, TX 77555-1062, USA
- School of Medicine, University of Texas Medical Branch, Galveston, TX 77555-1062, USA
| | - Sanaalarab Al-Enazy
- Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, TX 77555-1062, USA
| | - Menatallah M. Youssef
- Department of Pharmaceutical Analytical Chemistry, Ain-Shams University, Cairo 1156, Egypt
| | - Morgan Fisler
- Department of Obstetrics & Gynecology, Medical University of South Carolina, Charleston, SC 29425, USA
| | - Erik Rytting
- Department of Obstetrics & Gynecology, University of Texas Medical Branch, 301 University Boulevard, Galveston, TX 77555-1062, USA
- Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, TX 77555-1062, USA
- Correspondence:
| |
Collapse
|
6
|
Zheng Q, Zhou Q, Li J, Tian Y, Huang H, Yao Q, Wang J, Zhang J. Placental transfer of bromocriptine in an ex vivo human placental perfusion model. J Matern Fetal Neonatal Med 2017; 32:1155-1159. [PMID: 29103345 DOI: 10.1080/14767058.2017.1402000] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Abstract
Purpose: To determine the rate and extent of the maternal-fetal transplacental passage of bromocriptine (BCT) in the dually perfused human placental model. Methods: Twenty term placentas were included in an ex vivo human placental perfusion experiment with a closed-circuit model. At the start of the perfusion, BCT at the concentration of 10 or 100 ng/ml along with 100 µg/ml antipyrine which used as a positive marker were added to the maternal reservoir. Samples were collected for the measurements of BCT and markers of placental viability both from the maternal reservoir and fetal reservoir throughout the perfusion which lasted for 3 h. Determination of BCT was carried out with liquid chromatography-tandem mass spectrometry. Results: At the end of the study, the concentration in the fetal compartment was 0.82 ± 0.32 ng/ml in the low concentration group and 5.02 ± 0.97 ng/ml in the high concentration group with a fetal transfer rate of 6.13 ± 1.94% and 5.46 ± 0.87%, respectively. Conclusion: These data showed that only trace amount of BCT could transport across the human placenta in vitro which suggested that fetal exposure to maternally administered BCT may be insignificant. More additional studies are required to explore the safety of BCT administrated in pregnancy.
Collapse
Affiliation(s)
- Qiaoling Zheng
- a Department of Clinical Pharmacy , First Affiliated Hospital of Kunming Medical University , Kunming , China
| | - Qiong Zhou
- a Department of Clinical Pharmacy , First Affiliated Hospital of Kunming Medical University , Kunming , China
| | - Juan Li
- a Department of Clinical Pharmacy , First Affiliated Hospital of Kunming Medical University , Kunming , China
| | - Yuqin Tian
- b Department of Obstetrics and Gynecology , First Affiliated Hospital of Kunming Medical University , Kunming , China
| | - Hua Huang
- a Department of Clinical Pharmacy , First Affiliated Hospital of Kunming Medical University , Kunming , China
| | - Qin Yao
- a Department of Clinical Pharmacy , First Affiliated Hospital of Kunming Medical University , Kunming , China
| | - Jingjing Wang
- a Department of Clinical Pharmacy , First Affiliated Hospital of Kunming Medical University , Kunming , China
| | - Jun Zhang
- a Department of Clinical Pharmacy , First Affiliated Hospital of Kunming Medical University , Kunming , China
| |
Collapse
|
7
|
Al-Enazy S, Ali S, Albekairi N, El-Tawil M, Rytting E. Placental control of drug delivery. Adv Drug Deliv Rev 2017; 116:63-72. [PMID: 27527665 DOI: 10.1016/j.addr.2016.08.002] [Citation(s) in RCA: 61] [Impact Index Per Article: 8.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/14/2016] [Revised: 07/25/2016] [Accepted: 08/04/2016] [Indexed: 01/04/2023]
Abstract
The placenta serves as the interface between the maternal and fetal circulations and regulates the transfer of oxygen, nutrients, and waste products. When exogenous substances are present in the maternal bloodstream-whether from environmental contact, occupational exposure, medication, or drug abuse-the extent to which this exposure affects the fetus is determined by transport and biotransformation processes in the placental barrier. Advances in drug delivery strategies are expected to improve the treatment of maternal and fetal diseases encountered during pregnancy.
Collapse
|
8
|
Gopalakrishnan K, More AS, Hankins GD, Nanovskaya TN, Kumar S. Postnatal Cardiovascular Consequences in the Offspring of Pregnant Rats Exposed to Smoking and Smoking Cessation Pharmacotherapies. Reprod Sci 2017; 24:919-933. [PMID: 27733658 PMCID: PMC5933098 DOI: 10.1177/1933719116673199] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Approximately 20% of pregnant women smoke despite intentions to quit. Smoking cessation drugs, such as nicotine replacement therapy (NRT) and bupropion, are recommended treatments. Adverse cardiovascular outcomes in offspring have raised concerns about NRT's safety during pregnancy. However, the effect of bupropion is unknown. Using a rat model, we determined whether NRT and bupropion interventions during pregnancy are safer than continued smoking on offspring's cardiovascular function. Male offspring of controls and dams exposed to cigarette smoke (1.6 packs/day, inhalation), nicotine (2 mg/kg/d subcutaneously), and bupropion (13 mg/kg twice daily orally) were assessed for fetoplacental weight, cardiac function, blood pressure, and vascular reactivity. Fetoplacental weights were decreased and spontaneous beating and intracellular calcium in neonatal cardiomyocytes were increased in smoking, nicotine, and bupropion offspring; however, these effects were more accentuated in smoking followed by nicotine and bupropion offspring. Increased heart rate and decreased cardiac output, stroke volume, and left ventricular percent posterior wall thickening were observed in smoking, nicotine, and bupropion offspring. The left ventricular mass was reduced in smoking and nicotine but not in bupropion offspring. Blood pressure was higher with decreased endothelium-dependent relaxation and exaggerated vascular contraction to angiotensin II in smoking and nicotine offspring, with more pronounced dysfunctions in smoking than nicotine offspring. Maternal bupropion did not impact offspring's blood pressure, endothelium-dependent relaxation, and vascular contraction. In conclusion, maternal nicotine intervention adversely affects offspring's cardiovascular outcomes, albeit less severely than continued smoking. However, bupropion causes cardiac derangement in offspring but does not adversely affect blood pressure and vascular function.
Collapse
Affiliation(s)
- Kathirvel Gopalakrishnan
- Department of Obstetrics & Gynecology, The University of Texas Medical Branch, Galveston, TX, USA
| | - Amar S. More
- Department of Obstetrics & Gynecology, The University of Texas Medical Branch, Galveston, TX, USA
| | - Gary D. Hankins
- Department of Obstetrics & Gynecology, The University of Texas Medical Branch, Galveston, TX, USA
| | - Tatiana N. Nanovskaya
- Department of Obstetrics & Gynecology, The University of Texas Medical Branch, Galveston, TX, USA
| | - Sathish Kumar
- Department of Obstetrics & Gynecology, The University of Texas Medical Branch, Galveston, TX, USA
| |
Collapse
|
9
|
White SJ, Hendrickson HP, Atchley WT, Laurenzana EM, Gentry WB, Williams DK, Owens SM. Treatment with a monoclonal antibody against methamphetamine and amphetamine reduces maternal and fetal rat brain concentrations in late pregnancy. Drug Metab Dispos 2014; 42:1285-91. [PMID: 24839971 DOI: 10.1124/dmd.114.056879] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/15/2023] Open
Abstract
We hypothesized that treatment of pregnant rat dams with a dual reactive monoclonal antibody (mAb4G9) against (+)-methamphetamine [METH; equilibrium dissociation rate constant (KD) = 16 nM] and (+)-amphetamine (AMP; KD = 102 nM) could confer maternal and fetal protection from brain accumulation of both drugs of abuse. To test this hypothesis, pregnant Sprague-Dawley rats (on gestational day 21) received a 1 mg/kg i.v. METH dose, followed 30 minutes later by vehicle or mAb4G9 treatment. The mAb4G9 dose was 0.56 mole-equivalent in binding sites to the METH body burden. Pharmacokinetic analysis showed baseline METH and AMP elimination half-lives were congruent in dams and fetuses, but the METH volume of distribution in dams was nearly double the fetal values. The METH and AMP area under the serum concentration-versus-time curves from 40 minutes to 5 hours after mAb4G9 treatment increased >7000% and 2000%, respectively, in dams. Fetal METH serum did not change, but AMP decreased 23%. The increased METH and AMP concentrations in maternal serum resulted from significant increases in mAb4G9 binding. Protein binding changed from ∼15% to > 90% for METH and AMP. Fetal serum protein binding appeared to gradually increase, but the absolute fraction bound was trivial compared with the dams. mAb4G9 treatment significantly reduced METH and AMP brain values by 66% and 45% in dams and 44% and 46% in fetuses (P < 0.05), respectively. These results show anti-METH/AMP mAb4G9 therapy in dams can offer maternal and fetal brain protection from the potentially harmful effects of METH and AMP.
Collapse
Affiliation(s)
- Sarah J White
- Department of Pharmacology and Toxicology, College of Medicine (S.J.W., W.T.A., E.M.L., W.B.G., S.M.O.), Department of Anesthesiology, College of Medicine (W.B.G.), Department of Pharmaceutical Sciences, College of Pharmacy (H.P.H.), and Department of Biostatistics, College of Public Health (D.K.W.), University of Arkansas for Medical Sciences, Little Rock, Arkansas; and Department of Veterinary and Biomedical Sciences, College of Agricultural Sciences, Pennsylvania State University, State College, Pennsylvania (E.M.L.)
| | - Howard P Hendrickson
- Department of Pharmacology and Toxicology, College of Medicine (S.J.W., W.T.A., E.M.L., W.B.G., S.M.O.), Department of Anesthesiology, College of Medicine (W.B.G.), Department of Pharmaceutical Sciences, College of Pharmacy (H.P.H.), and Department of Biostatistics, College of Public Health (D.K.W.), University of Arkansas for Medical Sciences, Little Rock, Arkansas; and Department of Veterinary and Biomedical Sciences, College of Agricultural Sciences, Pennsylvania State University, State College, Pennsylvania (E.M.L.)
| | - William T Atchley
- Department of Pharmacology and Toxicology, College of Medicine (S.J.W., W.T.A., E.M.L., W.B.G., S.M.O.), Department of Anesthesiology, College of Medicine (W.B.G.), Department of Pharmaceutical Sciences, College of Pharmacy (H.P.H.), and Department of Biostatistics, College of Public Health (D.K.W.), University of Arkansas for Medical Sciences, Little Rock, Arkansas; and Department of Veterinary and Biomedical Sciences, College of Agricultural Sciences, Pennsylvania State University, State College, Pennsylvania (E.M.L.)
| | - Elizabeth M Laurenzana
- Department of Pharmacology and Toxicology, College of Medicine (S.J.W., W.T.A., E.M.L., W.B.G., S.M.O.), Department of Anesthesiology, College of Medicine (W.B.G.), Department of Pharmaceutical Sciences, College of Pharmacy (H.P.H.), and Department of Biostatistics, College of Public Health (D.K.W.), University of Arkansas for Medical Sciences, Little Rock, Arkansas; and Department of Veterinary and Biomedical Sciences, College of Agricultural Sciences, Pennsylvania State University, State College, Pennsylvania (E.M.L.)
| | - W Brooks Gentry
- Department of Pharmacology and Toxicology, College of Medicine (S.J.W., W.T.A., E.M.L., W.B.G., S.M.O.), Department of Anesthesiology, College of Medicine (W.B.G.), Department of Pharmaceutical Sciences, College of Pharmacy (H.P.H.), and Department of Biostatistics, College of Public Health (D.K.W.), University of Arkansas for Medical Sciences, Little Rock, Arkansas; and Department of Veterinary and Biomedical Sciences, College of Agricultural Sciences, Pennsylvania State University, State College, Pennsylvania (E.M.L.)
| | - D Keith Williams
- Department of Pharmacology and Toxicology, College of Medicine (S.J.W., W.T.A., E.M.L., W.B.G., S.M.O.), Department of Anesthesiology, College of Medicine (W.B.G.), Department of Pharmaceutical Sciences, College of Pharmacy (H.P.H.), and Department of Biostatistics, College of Public Health (D.K.W.), University of Arkansas for Medical Sciences, Little Rock, Arkansas; and Department of Veterinary and Biomedical Sciences, College of Agricultural Sciences, Pennsylvania State University, State College, Pennsylvania (E.M.L.)
| | - S Michael Owens
- Department of Pharmacology and Toxicology, College of Medicine (S.J.W., W.T.A., E.M.L., W.B.G., S.M.O.), Department of Anesthesiology, College of Medicine (W.B.G.), Department of Pharmaceutical Sciences, College of Pharmacy (H.P.H.), and Department of Biostatistics, College of Public Health (D.K.W.), University of Arkansas for Medical Sciences, Little Rock, Arkansas; and Department of Veterinary and Biomedical Sciences, College of Agricultural Sciences, Pennsylvania State University, State College, Pennsylvania (E.M.L.)
| |
Collapse
|
10
|
Rogers SW, Tvrdik P, Capecchi MR, Gahring LC. Prenatal ablation of nicotinic receptor alpha7 cell lineages produces lumbosacral spina bifida the severity of which is modified by choline and nicotine exposure. Am J Med Genet A 2012; 158A:1135-44. [PMID: 22473653 PMCID: PMC3415211 DOI: 10.1002/ajmg.a.35372] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/03/2012] [Accepted: 02/26/2012] [Indexed: 12/29/2022]
Abstract
Lumbosacral spina bifida is a common debilitating birth defect whose multiple causes are poorly understood. Here, we provide the first genetic delineation of cholinergic nicotinic receptor alpha7 (Chrna7) expression and link the ablation of the Chrna7 cell lineage to this condition in the mouse. Using homologous recombination, an IRES-Cre bi-cistronic cassette was introduced into the 3′ noncoding region of Chrna7 (Chrna7:Cre) for identifying cell lineages expressing this gene. This lineage first appears at embryonic day E9.0 in rhombomeres 3 and 5 of the neural tube and extends to cell subsets in most tissues by E14.5. Ablation of the Chrna7:Cre cell lineage in embryos from crosses with conditionally expressed attenuated diphtheria toxin results in precise developmental defects including omphalocele (89%) and open spina bifida (SB; 80%). We hypothesized that like humans, this defect would be modified by environmental compounds not only folic acid or choline but also nicotine. Prenatal chronic oral nicotine administration substantially worsened the defect to often include the rostral neural tube. In contrast, supplementation of the maternal diet with 2% choline decreased SB prevalence to 38% and dramatically reduced the defect severity. Folic acid supplementation only trended towards a reduced SB frequency. The omphalocele was unaffected by these interventions. These studies identify the Chrna7 cell lineage as participating in posterior neuropore closure and present a novel model of lower SB that can be substantially modified by the prenatal environment. © 2012 Wiley Periodicals, Inc.
Collapse
Affiliation(s)
- Scott W Rogers
- Salt Lake City VA Geriatric Research, Education and Clinical Center, Salt Lake City, Utah, USA.
| | | | | | | |
Collapse
|
11
|
Ottney AR. Nicotine Conjugate Vaccine as a Novel Approach to Smoking Cessation. Pharmacotherapy 2011; 31:703-13. [DOI: 10.1592/phco.31.7.703] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
|
12
|
Hubbard JJ, Laurenzana EM, Williams DK, Gentry WB, Owens SM. The fate and function of therapeutic antiaddiction monoclonal antibodies across the reproductive cycle of rats. J Pharmacol Exp Ther 2010; 336:414-22. [PMID: 20962030 DOI: 10.1124/jpet.110.175083] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022] Open
Abstract
During preclinical development of neuroprotective antiaddiction therapeutic monoclonal antibodies (mAbs) against phencyclidine (PCP) and (+)-methamphetamine, we discovered novel, gestation stage-specific changes in mAb disposition spanning the entire reproductive cycle of female rats. Each pharmacological change was independent of mAb dose and antigen target but was precisely coincident with transitions between the gestational trimesters, parturition, and lactation periods of the female reproductive cycle. Whereas anti-PCP mAb6B5 terminal elimination half-life (t(1/2λz)) in nonpregnant females was 6.6 ± 1.6 days, the mAb6B5 t(1/2λz) significantly changed to 3.7 ± 0.4 days, then 1.4 ± 0.1 days, then 3.0 ± 0.4 days in the second trimester, third trimester, and postpartum periods, respectively (p < 0.05 for each change). Initially, these evolving changes in mAb6B5 clearance (3.3-fold), distribution volume (1.8-fold), and elimination half-life (4.7-fold) affected our ability to sustain sufficient mAb6B5 levels to sequester PCP in the bloodstream. However, understanding the mechanisms underlying each transition allowed development of an adaptive mAb-dosing paradigm, which substantially reduced PCP levels in dam brains and fetuses throughout pregnancy. These mAb functional studies also revealed that antidrug mAbs readily cross the placenta before syncytiotrophoblast barrier maturation, demonstrating the dynamic nature of mAb pharmacokinetics in pregnancy and the importance of maintaining maternal mAb levels. These studies provide the first preclinical pregnancy model in any species for chronic mAb dosing and could have important implications for the use of antibody therapies involving blood organ barriers (such as addiction) or other chronic diseases in women of childbearing age (e.g., irritable bowel diseases, multiple sclerosis, breast cancer, rheumatoid arthritis).
Collapse
Affiliation(s)
- Jonathan J Hubbard
- Department of Pharmacology and Toxicology, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, USA
| | | | | | | | | |
Collapse
|
13
|
Hemauer SJ, Patrikeeva SL, Wang X, Abdelrahman DR, Hankins GDV, Ahmed MS, Nanovskaya TN. Role of transporter-mediated efflux in the placental biodisposition of bupropion and its metabolite, OH-bupropion. Biochem Pharmacol 2010; 80:1080-6. [PMID: 20599802 DOI: 10.1016/j.bcp.2010.06.025] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/26/2010] [Revised: 06/10/2010] [Accepted: 06/14/2010] [Indexed: 10/19/2022]
Abstract
Cigarette smoking during pregnancy is a preventable risk factor associated with maternal and fetal complications. Bupropion is an antidepressant used successfully for smoking cessation in non-pregnant patients. Our goal is to determine whether it could benefit the pregnant patient seeking smoking cessation. The aim of this investigation was to determine the role of human placenta in the disposition of bupropion and its major hepatic metabolite, OH-bupropion. The expression of efflux transporters P-gp and BCRP was determined in placental brush border membrane (n=200) and revealed a positive correlation (p<0.05). Bupropion was transported by BCRP (K(t) 3 microM, V(max) 30 pmol/mg protein/min) and P-gp (K(t) 0.5 microM, V(max) 6 pmol/mg protein min) in placental inside-out vesicles (IOVs). OH-bupropion crossed the dually-perfused human placental lobule without undergoing further metabolism, nor was it an efflux substrate of P-gp or BCRP. In conclusion, our data indicate that human placenta actively regulates the disposition of bupropion (via metabolism, active transport), but not its major hepatic metabolite, OH-bupropion.
Collapse
Affiliation(s)
- Sarah J Hemauer
- Department of Obstetrics & Gynecology, University of Texas Medical Branch, 301 University Boulevard, Galveston, TX 77555-0587, USA.
| | | | | | | | | | | | | |
Collapse
|
14
|
Lazic T, Matic M, Gallup JM, Van Geelen A, Meyerholz DK, Grubor B, Imerman PM, de-Macedo MMMA, Ackermann MR. Effects of nicotine on pulmonary surfactant proteins A and D in ovine lung epithelia. Pediatr Pulmonol 2010; 45:255-62. [PMID: 20131324 PMCID: PMC2981073 DOI: 10.1002/ppul.21153] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Abstract
Maternal smoking during pregnancy increases the incidence and severity of respiratory infections in neonates. Surfactant proteins A and D (SP-A and SP-D, respectively) are components of pulmonary innate immunity and have an important role in defense against inhaled pathogens. The purpose of this study was to determine if nicotine exposure during the third trimester of pregnancy alters the expression of SP-A and SP-D of fetal lung epithelia. Pregnant ewes were assigned to four groups; a nicotine-exposed full-term and pre-term group, and control full-term and pre-term group. Lung tissue was collected for Western blot and IHC analysis of SP-A level, Western blot analysis of SP-D level and qPCR analysis of SP-A and SP-D mRNA expression. Exposure to nicotine significantly decreased SP-A gene expression (P = 0.01) and SP-A protein level in pre-term lambs. This finding suggests that maternal nicotine exposure during the last trimester of pregnancy alters a key component of lung innate immunity in offspring.
Collapse
Affiliation(s)
- Tatjana Lazic
- Department of Veterinary Pathology, 2740 College of Veterinary Medicine, Iowa State University, Ames, IA 50011-1250, USA.
| | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Moreno AY, Janda KD. Immunopharmacotherapy: vaccination strategies as a treatment for drug abuse and dependence. Pharmacol Biochem Behav 2009; 92:199-205. [PMID: 19350728 DOI: 10.1016/j.pbb.2009.01.015] [Citation(s) in RCA: 47] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Abstract
Despite intensive efforts for its eradication, addiction to both legal and illicit drugs continues to be a major worldwide medical and social problem. Drug addiction is defined as a disease state in which the body relies on a substance for normal functioning and develops physical dependence leading to compulsive and repetitive use despite negative consequences to the user's health, mental state or social life. Psychoactive substances such as cocaine, nicotine, alcohol, and amphetamines are able to cross the blood-brain barrier once ingested and temporarily alter the chemical balance of the brain. Current medications used for the treatment of dependence are typically agonists or antagonists of the drugs of abuse. The complex interrelations of the neuronal circuits have made it difficult to accurately predict the actions of potential agonist/antagonist drugs and have led to undesirable side effects within the central nervous system. Nearly forty years ago, a handful of groups began to explore the possibility of utilizing an individual's own immune machinery to counteract the effects of drug exposure in an approach later termed by our laboratory, immunopharmacotherapy.Immunopharmacotherapy aims to use highly specific antibodies to sequester the drug of interest while the latter is still in the bloodstream. Thus, creation of the antibody-drug complex will blunt crossing of the blood brain barrier (BBB) not only counteracting the reinforcing effects of the drug but also preventing any detrimental side effects on the CNS. In the present mini-review we aim to present a focused summary, including relevant challenges and future directions, of the current state of cocaine and nicotine vaccines as these two programs have been the most successful to date.
Collapse
Affiliation(s)
- Amira Y Moreno
- Department of Chemistry, the Skaggs Institute for Chemical Biology and the Worm Institute of Research and Medicine (WIRM), The Scripps Research Institute, 10550 N, Torrey Pines Road, La Jolla, California 92037, USA
| | | |
Collapse
|
16
|
Maternal smoking in pregnancy and externalizing behavior in 18-month-old children: results from a population-based prospective study. J Am Acad Child Adolesc Psychiatry 2009; 48:283-289. [PMID: 19242291 DOI: 10.1097/chi.0b013e318195bcfb] [Citation(s) in RCA: 57] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
OBJECTIVE The relation between prenatal smoking and child behavioral problems has been investigated in children of school age and older, but prospective studies in younger children are lacking. Using the population-based prospective Norwegian Mother and Child Cohort Study, we examined the risk for externalizing behaviors among 18-month-old children after exposure to maternal smoking during pregnancy. METHOD Participants were 22,545 mothers and their 18-month-old children. Mothers reported their smoking habits at the 17th week of gestation and their child's externalizing behavior at 18 months of age by means of standardized questionnaires. Data were analyzed using logistic regression, with scores of externalizing behavior above the 88.6th percentile as the dependent variable and self-reported smoking as the independent variable. We examined the child's sex as a possible moderator. RESULTS We documented a threshold effect of smoking 10 cigarettes or more per day during pregnancy on subsequent externalizing behaviors among 18-month-old children, even after adjusting for relevant confounders (odds ratio 1.32, 95% confidence interval 1.03-1.70). The child's sex did not moderate these effects (odds ratio 0.98, 95% confidence interval 0.83-1.16). CONCLUSIONS Maternal smoking during pregnancy increases offspring's subsequent risk for externalizing behavior problems at 18 months of age. The pattern of risk does not differ between boys and girls. Our findings suggest a population attributable risk of 1.75% [corrected] (i.e., the proportion of externalizing cases that could potentially be avoided if prenatal smoking was eliminated or reduced to fewer than 10 cigarettes per day).
Collapse
|
17
|
Keyler DE, Lesage MG, Dufek MB, Pentel PR. Changes in maternal and fetal nicotine distribution after maternal administration of monoclonal nicotine-specific antibody to rats. Int Immunopharmacol 2006; 6:1665-72. [PMID: 16979120 PMCID: PMC2727278 DOI: 10.1016/j.intimp.2006.06.013] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/26/2006] [Accepted: 06/30/2006] [Indexed: 11/19/2022]
Abstract
Vaccination against nicotine to elicit the production of nicotine-specific antibodies is a potential treatment for tobacco addiction which reduces nicotine distribution from serum to brain. Vaccination of pregnant rats also reduces the distribution of maternally-administered nicotine to the fetal brain. Whether this is due to maternal antibody reducing the transfer of nicotine from mother to fetus, or to fetal antibody altering the distribution of nicotine within the fetus, is not clear. In the current study, passive immunization of rats with the murine monoclonal nicotine-specific antibody Nic311 was used as a surrogate for vaccination because antibody transfer to the fetus was anticipated to be lower than with vaccination. Pregnant rats received nicotine from gestational day (GD) 18-20 as frequent i.v. boluses to simulate nicotine exposure from smoking. Nic311 was administered at doses of 30, 80 or 240 mg/kg on GD 19. Fetal serum Nic311 levels on GD 20 were <3% of concurrent maternal levels, but concentrations of up to 20 ug/ml in fetal serum were obtained owing to the very high levels in maternal serum. Accumulation of the chronically administered nicotine, measured on GD 20, was not changed by Nic311 treatment in either maternal or fetal brain. The early distribution of nicotine to maternal brain, measured 5 min after a dose, was markedly reduced by Nic311, while the early distribution of nicotine to whole fetus and fetal brain was not substantially altered. These data suggest that the limited transfer of Nic311 to the fetus in turn limits the ability of Nic311 to reduce nicotine distribution to the fetal brain.
Collapse
Affiliation(s)
- D E Keyler
- College of Pharmacy, University of Minnesota Minneapolis, MN, United States; Minneapolis Medical Research Foundation, Minneapolis, MN, United States
| | | | | | | |
Collapse
|